Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam(The University of Texas MD Anderson Cancer Center), Roza Nurieva(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center), Naimah Turner(The University of Texas MD Anderson Cancer Center), Nicolas L. Palaskas(The University of Texas MD Anderson Cancer Center), Karin Woodman(The University of Texas MD Anderson Cancer Center), Yuanteng Jeff Li(The University of Texas MD Anderson Cancer Center), Monica Loghin(The University of Texas MD Anderson Cancer Center), Ajay Sheshadri(University of Monterrey), Sayan Alekseev(The University of Texas MD Anderson Cancer Center), Rayansh Poojary, Anisha B. Patel(The University of Texas MD Anderson Cancer Center), Jocelynn Colunga-Minutti(The University of Texas MD Anderson Cancer Center), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Fernanda G. Kugeratski(The University of Texas MD Anderson Cancer Center), Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Rene Rico(The University of Texas MD Anderson Cancer Center), Ashley Aaroe(The University of Texas MD Anderson Cancer Center)
Cited by 56
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338